CO2019010578A2 - Derivados de fenilo como moduladores del receptor de pge2 - Google Patents
Derivados de fenilo como moduladores del receptor de pge2Info
- Publication number
- CO2019010578A2 CO2019010578A2 CONC2019/0010578A CO2019010578A CO2019010578A2 CO 2019010578 A2 CO2019010578 A2 CO 2019010578A2 CO 2019010578 A CO2019010578 A CO 2019010578A CO 2019010578 A2 CO2019010578 A2 CO 2019010578A2
- Authority
- CO
- Colombia
- Prior art keywords
- modulators
- formula
- phenyl derivatives
- pge2 receptor
- relates
- Prior art date
Links
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title abstract 2
- 102000008866 Prostaglandin E receptors Human genes 0.000 title 1
- 108010088540 Prostaglandin E receptors Proteins 0.000 title 1
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 101150109738 Ptger4 gene Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000001907 coumarones Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- 150000003180 prostaglandins Chemical class 0.000 abstract 1
- 230000007420 reactivation Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a derivados de fenilo de fórmula (I); donde (R1)n, R3, R4a, R4b, R5a, R5b y Ar1 son como se describen en la descripción y su uso en el tratamiento del cáncer mediante la modulación de una respuesta inmune que comprende una reactivación del sistema inmune en el tumor. La invención se refiere además a nuevos derivados de benzofurano y benzotiofeno de fórmula (III) y su uso como productos farmacéuticos, a su preparación, a las sales aceptables para uso farmacéuticos de los mismos, y a su uso como productos farmacéuticos, a composiciones farmacéuticas que contienen uno o más compuestos de fórmula (I), y especialmente a su uso como moduladores de los receptores EP2 y/o EP4 de la prostaglandina 2.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2017062031 | 2017-05-18 | ||
| PCT/EP2018/062862 WO2018210994A1 (en) | 2017-05-18 | 2018-05-17 | Phenyl derivatives as pge2 receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2019010578A2 true CO2019010578A2 (es) | 2019-10-09 |
Family
ID=62186480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2019/0010578A CO2019010578A2 (es) | 2017-05-18 | 2019-09-27 | Derivados de fenilo como moduladores del receptor de pge2 |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US11712438B2 (es) |
| EP (1) | EP3625222B1 (es) |
| JP (1) | JP7159214B2 (es) |
| KR (1) | KR102632028B1 (es) |
| CN (1) | CN110612296A (es) |
| AR (1) | AR111941A1 (es) |
| AU (1) | AU2018269666B2 (es) |
| BR (1) | BR112019024109A2 (es) |
| CA (1) | CA3060597A1 (es) |
| CL (1) | CL2019003275A1 (es) |
| CO (1) | CO2019010578A2 (es) |
| CR (1) | CR20190559A (es) |
| CY (1) | CY1124608T1 (es) |
| DK (1) | DK3625222T3 (es) |
| EA (1) | EA201992676A1 (es) |
| ES (1) | ES2893452T3 (es) |
| HR (1) | HRP20211533T1 (es) |
| HU (1) | HUE056080T2 (es) |
| IL (1) | IL270623B2 (es) |
| LT (1) | LT3625222T (es) |
| MA (1) | MA49126B1 (es) |
| MX (1) | MX388256B (es) |
| PE (1) | PE20191814A1 (es) |
| PH (1) | PH12019502563A1 (es) |
| PL (1) | PL3625222T3 (es) |
| PT (1) | PT3625222T (es) |
| RS (1) | RS62440B1 (es) |
| SG (1) | SG11201908729UA (es) |
| SI (1) | SI3625222T1 (es) |
| TW (1) | TWI765041B (es) |
| UA (1) | UA125123C2 (es) |
| WO (1) | WO2018210994A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| CN110621671A (zh) | 2017-05-18 | 2019-12-27 | 爱杜西亚药品有限公司 | 作为pge2受体调节剂的苯并呋喃及苯并噻吩衍生物 |
| PE20191811A1 (es) | 2017-05-18 | 2019-12-26 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de pge2 |
| EP3625223B1 (en) | 2017-05-18 | 2021-08-11 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives |
| CN111819193A (zh) | 2018-01-05 | 2020-10-23 | 西奈山伊坎医学院 | 增加胰腺β细胞增殖的方法、治疗方法以及组合物 |
| CA3093340A1 (en) | 2018-03-20 | 2019-09-26 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| US20220064146A1 (en) * | 2018-12-31 | 2022-03-03 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| US20230390303A1 (en) | 2020-11-13 | 2023-12-07 | Ono Pharmaceutical Co., Ltd. | Cancer treatment by combination of ep4 antagonist and immune checkpoint inhibitor |
| JP2024524981A (ja) | 2021-06-24 | 2024-07-09 | レザボア ニューロサイエンス，インコーポレイテッド | Ｅｐ２アンタゴニスト化合物 |
| WO2025229177A1 (en) | 2024-05-02 | 2025-11-06 | Idorsia Pharmaceuticals Ltd | Crystalline forms of an n-substituted indole derivative |
Family Cites Families (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5948786A (en) | 1996-04-12 | 1999-09-07 | Sumitomo Pharmaceuticals Company, Limited | Piperidinylpyrimidine derivatives |
| ATE395058T1 (de) | 2000-03-24 | 2008-05-15 | Asterand Uk Ltd | Verwendung von prostanoid-ep4-rezeptor- antagonisten zur behandlung von kopfschmerzen und nachweisverfahren für solche antagonisten |
| HN2001000224A (es) | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
| GB0031295D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Naphthalene derivatives |
| GB0031302D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Napthalene derivatives |
| GB0103269D0 (en) | 2001-02-09 | 2001-03-28 | Glaxo Group Ltd | Napthalene derivatives |
| MXPA04009961A (es) | 2002-04-12 | 2004-12-13 | Pfizer | Compuestos de imidazol como agentes anti-inflamatorios y analgesicos. |
| CA2482382A1 (en) | 2002-04-12 | 2003-10-23 | Pfizer Inc. | Pyrazole compounds as anti-inflammatory and analgesic agents |
| AU2003233297A1 (en) | 2002-05-23 | 2003-12-12 | Theratechnologies Inc | Antagonistic peptides of prostaglandin e2 receptor subtype ep4 |
| DE602004013938D1 (de) | 2003-01-29 | 2008-07-03 | Asterand Uk Ltd | Hemmstoffe des ep4-rezeptors |
| CA2536887C (en) | 2003-08-26 | 2012-03-06 | Teijin Pharma Limited | Pyrrolopyrimidinone derivatives |
| WO2005021508A1 (en) | 2003-09-03 | 2005-03-10 | Pfizer Inc. | Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists |
| US8084457B2 (en) | 2003-09-15 | 2011-12-27 | Lead Discovery Center Gmbh | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
| GB0324269D0 (en) | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| AU2005238291A1 (en) | 2004-05-04 | 2005-11-10 | Pfizer Inc. | Substituted methyl aryl or heteroaryl amide compounds |
| BRPI0510598A (pt) | 2004-05-04 | 2007-11-20 | Pfizer | compostos de amida de aril ou heteroaril substituìdos |
| GT200500284A (es) | 2004-10-15 | 2006-03-27 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
| AU2006246930C1 (en) | 2005-05-19 | 2012-01-19 | Merck Canada Inc. | Quinoline derivatives as EP4 antagonists |
| WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
| DOP2007000068A (es) | 2006-04-12 | 2007-10-31 | Sanofi Aventis Us Llc | Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2 |
| EP2013169B1 (en) | 2006-04-24 | 2012-08-22 | Merck Canada Inc. | Indole amide derivatives as ep4 receptor antagonists |
| EP2035376B1 (en) | 2006-06-12 | 2014-08-27 | Merck Canada Inc. | Indoline amide derivatives as ep4 receptor ligands |
| US20080280891A1 (en) | 2006-06-27 | 2008-11-13 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
| WO2008008059A1 (en) | 2006-07-12 | 2008-01-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents ans uses thereof |
| ES2393932T3 (es) | 2006-07-14 | 2013-01-02 | Novartis Ag | Derivados de Pirimidina como inhibidores de ALK-5 |
| CN101541778B (zh) | 2006-08-11 | 2014-10-08 | 默克加拿大有限公司 | 作为ep4受体配体的噻吩甲酰胺衍生物 |
| WO2008039882A1 (en) | 2006-09-30 | 2008-04-03 | Sanofi-Aventis U.S. Llc | A combination of niacin and a prostaglandin d2 receptor antagonist |
| US8158671B2 (en) | 2007-02-26 | 2012-04-17 | Merck Canada Inc. | Indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists |
| JP2010522218A (ja) | 2007-03-26 | 2010-07-01 | メルク フロスト カナダ リミテツド | Ｅｐ４受容体アンタゴニストとしてのナフタレン及びキノリンスルホニル尿素誘導体 |
| CA2681861A1 (en) | 2007-03-26 | 2008-10-16 | Astellas Pharma Inc. | Ornithine derivative |
| EP2014657A1 (de) * | 2007-06-21 | 2009-01-14 | Bayer Schering Pharma Aktiengesellschaft | Diaminopyrimidine als Modulatoren des EP2-Rezeptors |
| US20110028463A1 (en) | 2007-07-03 | 2011-02-03 | Astellas Pharma Inc. | Amide compounds |
| AU2008309517B2 (en) | 2007-10-12 | 2013-03-14 | Astrazeneca Ab | Inhibitors of protein kinases |
| CA2714743C (en) | 2008-02-19 | 2017-01-17 | Janssen Pharmaceutica N.V. | Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase |
| SI2565191T1 (sl) | 2008-05-14 | 2014-12-31 | Astellas Pharma Inc. | Derivati 4-(indol-7-ilkarbonilaminometil)cikloheksan karboksilne kisline kot EP4 receptorski antagonisti, uporabni za zdravljenje kronične ledvične odpovedi ali diabetične nefropatije |
| US20130225528A1 (en) | 2008-05-21 | 2013-08-29 | Ariad Pharmaceuticals, Inc. | Phosphorus Derivatives as Kinase Inhibitors |
| CN102149384B (zh) | 2008-08-14 | 2014-08-20 | 南京奥昭生物科技有限公司 | 作为ep4受体拮抗剂的杂环酰胺衍生物 |
| US9029414B2 (en) | 2008-09-19 | 2015-05-12 | Biotechnology Research Corporation | Triterpenoid compounds and methods of use thereof |
| CN102224154A (zh) | 2008-09-25 | 2011-10-19 | 默克弗罗斯特加拿大有限公司 | 作为EP4受体拮抗剂的β-咔啉磺酰脲衍生物 |
| WO2011022348A1 (en) | 2009-08-18 | 2011-02-24 | Janssen Pharmaceutica Nv | Ethylene diamine modulators of fatty acid amide hydrolase |
| US20110124667A1 (en) | 2009-11-23 | 2011-05-26 | Philip Manton Brown | Methods for the treatment of irritable bowel syndrome |
| BR112012029647A2 (pt) | 2010-05-21 | 2016-08-02 | Chemilia Ab | novos derivados de pirimidinas |
| HRP20170042T1 (hr) | 2010-09-21 | 2017-03-10 | Eisai R&D Management Co., Ltd. | Farmaceutski pripravak |
| CN106046158A (zh) | 2010-09-29 | 2016-10-26 | 株式会社Nb健康研究所 | 针对人前列腺素e2 受体ep4 的抗体 |
| WO2012066070A1 (en) | 2010-11-17 | 2012-05-24 | Novartis Ag | 3-(aminoaryl)-pyridine compounds |
| WO2012066065A1 (en) | 2010-11-17 | 2012-05-24 | Novartis Ag | Phenyl-heteroaryl amine compounds and their uses |
| CA2820109C (en) | 2010-12-10 | 2018-01-09 | Rottapharm S.P.A. | Pyridine amide derivatives as ep4 receptor antagonists |
| WO2012103071A2 (en) | 2011-01-25 | 2012-08-02 | Eisai R&D Management Co., Ltd. | Compounds and compositions |
| BR112013024378A2 (pt) | 2011-03-24 | 2016-12-13 | Chemilia Ab | novos derivados de pirimidina |
| WO2012149528A1 (en) | 2011-04-29 | 2012-11-01 | Exelixis, Inc. | Inhibitors of inducible form of 6-phosphofructose-2-kinase |
| US9518044B2 (en) | 2011-06-20 | 2016-12-13 | Emory University | Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto |
| CN103702980B (zh) | 2011-07-04 | 2016-10-05 | 罗达制药生物技术有限责任公司 | 环胺衍生物作为ep4受体拮抗剂 |
| EP2554662A1 (en) | 2011-08-05 | 2013-02-06 | M Maria Pia Cosma | Methods of treatment of retinal degeneration diseases |
| WO2013090552A1 (en) | 2011-12-13 | 2013-06-20 | Yale University | Compositions and methods for reducing ctl exhaustion |
| US9296701B2 (en) * | 2012-04-24 | 2016-03-29 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
| JO3296B1 (ar) | 2012-06-29 | 2018-09-16 | Lilly Co Eli | مركبات فينوكسي إيثيل بيبريدين |
| TWI572597B (zh) | 2012-06-29 | 2017-03-01 | 美國禮來大藥廠 | 二甲基－苯甲酸化合物 |
| EP2711364A1 (en) | 2012-09-21 | 2014-03-26 | Chemilia AB | 4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer |
| BR112015011497B1 (pt) | 2012-11-27 | 2023-01-10 | Thomas Helledays Stiftelse För Medicinsk Forskning | Composto, e, formulação farmacêutica |
| UA115576C2 (uk) | 2012-12-06 | 2017-11-27 | Байєр Фарма Акцієнгезелльшафт | Похідні бензимідазолу як антагоністи ер4 |
| EP2765128A1 (en) | 2013-02-07 | 2014-08-13 | Almirall, S.A. | Substituted benzamides with activity towards EP4 receptors |
| TW201443004A (zh) | 2013-02-15 | 2014-11-16 | Lilly Co Eli | 苯氧基乙氧基化合物 |
| TWI636046B (zh) | 2013-05-17 | 2018-09-21 | 美國禮來大藥廠 | 苯氧基乙基二氫－１ｈ－異喹啉化合物 |
| MY173564A (en) | 2013-05-30 | 2020-02-04 | Idorsia Pharmaceuticals Ltd | Cxcr7 receptor modulators |
| SG11201510121RA (en) | 2013-06-12 | 2016-01-28 | Kaken Pharma Co Ltd | 4-alkynyl imidazole derivative and medicine comprising same as active ingredient |
| WO2015034820A1 (en) | 2013-09-04 | 2015-03-12 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| ES2675027T3 (es) | 2013-09-06 | 2018-07-05 | Aurigene Discovery Technologies Limited | Derivados de 1,2,4-oxadiazol como inmunomoduladores |
| WO2015044900A1 (en) | 2013-09-27 | 2015-04-02 | Aurigene Discovery Technologies Limited | Therapeutic immunomodulating compounds |
| SI3057953T1 (sl) | 2013-10-17 | 2018-12-31 | Vertex Pharmaceuticals Incorporated | Ko-kristali(s)-n-metil-8-(1-((2'-metil-(4,5'-bipimiridin)-6-il)amino) propan-2-il)kinolin-4-karboksamida in njegovi devterirani derivati kot inhibitorji dna-pk |
| JP6374959B2 (ja) * | 2013-10-17 | 2018-08-15 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ｄｎａ−ｐｋ阻害剤 |
| DK3083554T3 (da) | 2013-12-17 | 2019-05-13 | Lilly Co Eli | Dimethylbenzoesyreforbindelser |
| RS56615B1 (sr) | 2013-12-17 | 2018-02-28 | Lilly Co Eli | Derivati fenoksietil cikličnih amina i njihova aktivnost kao modulatora ep4 receptora |
| TW201607943A (zh) | 2013-12-19 | 2016-03-01 | 拜耳製藥公司 | 作為ｅｐ４配體之新穎苯并咪唑衍生物 |
| TW201623277A (zh) | 2014-03-26 | 2016-07-01 | 安斯泰來製藥股份有限公司 | 醯胺化合物 |
| WO2015167825A1 (en) | 2014-04-29 | 2015-11-05 | Emory University | Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto |
| CN110354266A (zh) | 2014-05-23 | 2019-10-22 | 卫材 R&D 管理有限公司 | 用于治疗癌症的组合疗法 |
| JP6635949B2 (ja) | 2014-06-04 | 2020-01-29 | トーマス・ヘレデイズ・スティフテルス・フォー・メディシンスク・フォルスクニング | 炎症性および自己免疫性の病気の処置のためのｍｔｈ１阻害剤 |
| AP2017009690A0 (en) | 2014-06-19 | 2017-01-31 | Ariad Pharma Inc | Heteroaryl compounds for kinase inhibition |
| WO2016021742A1 (en) | 2014-08-07 | 2016-02-11 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds as ep4 receptor antagonists |
| TWI739666B (zh) | 2015-01-09 | 2021-09-11 | 日商小野藥品工業股份有限公司 | 醫藥組成物 |
| JP6689297B2 (ja) | 2015-07-23 | 2020-04-28 | 武田薬品工業株式会社 | 複素環化合物 |
| KR102684436B1 (ko) | 2015-10-16 | 2024-07-15 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Ep4 길항제 |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| EP4219462A1 (en) | 2016-07-13 | 2023-08-02 | Vertex Pharmaceuticals Incorporated | Methods, compositions and kits for increasing genome editing efficiency |
| CN110621671A (zh) | 2017-05-18 | 2019-12-27 | 爱杜西亚药品有限公司 | 作为pge2受体调节剂的苯并呋喃及苯并噻吩衍生物 |
| PE20191811A1 (es) | 2017-05-18 | 2019-12-26 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de pge2 |
| JP7065117B2 (ja) | 2017-05-18 | 2022-05-11 | イドーシア ファーマシューティカルズ リミテッド | Ｎ－置換インドール誘導体 |
| EP3625223B1 (en) | 2017-05-18 | 2021-08-11 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives |
-
2018
- 2018-05-17 PE PE2019002396A patent/PE20191814A1/es unknown
- 2018-05-17 LT LTEPPCT/EP2018/062862T patent/LT3625222T/lt unknown
- 2018-05-17 MA MA49126A patent/MA49126B1/fr unknown
- 2018-05-17 CA CA3060597A patent/CA3060597A1/en active Pending
- 2018-05-17 JP JP2019563491A patent/JP7159214B2/ja active Active
- 2018-05-17 BR BR112019024109-4A patent/BR112019024109A2/pt not_active IP Right Cessation
- 2018-05-17 CN CN201880031321.4A patent/CN110612296A/zh active Pending
- 2018-05-17 HU HUE18725222A patent/HUE056080T2/hu unknown
- 2018-05-17 PL PL18725222T patent/PL3625222T3/pl unknown
- 2018-05-17 MX MX2019013718A patent/MX388256B/es unknown
- 2018-05-17 WO PCT/EP2018/062862 patent/WO2018210994A1/en not_active Ceased
- 2018-05-17 DK DK18725222.6T patent/DK3625222T3/da active
- 2018-05-17 SG SG11201908729U patent/SG11201908729UA/en unknown
- 2018-05-17 TW TW107116759A patent/TWI765041B/zh not_active IP Right Cessation
- 2018-05-17 RS RS20211256A patent/RS62440B1/sr unknown
- 2018-05-17 IL IL270623A patent/IL270623B2/en unknown
- 2018-05-17 KR KR1020197037298A patent/KR102632028B1/ko active Active
- 2018-05-17 PT PT18725222T patent/PT3625222T/pt unknown
- 2018-05-17 CR CR20190559A patent/CR20190559A/es unknown
- 2018-05-17 AR ARP180101315A patent/AR111941A1/es not_active Application Discontinuation
- 2018-05-17 UA UAA201911975A patent/UA125123C2/uk unknown
- 2018-05-17 SI SI201830422T patent/SI3625222T1/sl unknown
- 2018-05-17 ES ES18725222T patent/ES2893452T3/es active Active
- 2018-05-17 US US16/614,594 patent/US11712438B2/en active Active
- 2018-05-17 AU AU2018269666A patent/AU2018269666B2/en not_active Ceased
- 2018-05-17 HR HRP20211533TT patent/HRP20211533T1/hr unknown
- 2018-05-17 EP EP18725222.6A patent/EP3625222B1/en active Active
- 2018-05-17 EA EA201992676A patent/EA201992676A1/ru unknown
-
2019
- 2019-09-27 CO CONC2019/0010578A patent/CO2019010578A2/es unknown
- 2019-11-15 CL CL2019003275A patent/CL2019003275A1/es unknown
- 2019-11-15 PH PH12019502563A patent/PH12019502563A1/en unknown
-
2021
- 2021-10-19 CY CY20211100906T patent/CY1124608T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019010505A2 (es) | Derivados de pirimidina como moduladores del receptor de pge2 | |
| CO2019010578A2 (es) | Derivados de fenilo como moduladores del receptor de pge2 | |
| CL2018001325A1 (es) | Derivados de indol n-sustituidos como moduladores del receptor de pge2 | |
| ECSP20070854A (es) | Compuestos heteroaril tetracíclicos | |
| MX2019004685A (es) | Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3f] isoquinolina utiles en el tratamiento del cancer. | |
| CU24487B1 (es) | Compuestos de tetrahidroquinolinona sustituidos como moduladores de gamma ror | |
| MX2019013639A (es) | Derivados de indol n-sustituidos. | |
| MX393586B (es) | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue | |
| ECSP19062381A (es) | Moduladores del receptor de estrógeno | |
| CL2015002466A1 (es) | Formulaciones de compuestos orgánicos | |
| MX2020003732A (es) | Derivado de anillo fusionado como inhibidor del receptor a2a. | |
| EA201791396A1 (ru) | ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ | |
| EA201791397A1 (ru) | СВЯЗАННЫЕ С ГЕТЕРОЦИКЛИЛАМИ ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ | |
| ECSP22007557A (es) | Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 | |
| MX2019014940A (es) | Moduladores de tetrahidropiridopirazinas del receptor 6 acoplado a la proteina g (gpr6). |